Safety reporting requirements in the post marketing phase. Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
|
|
- Edith Hall
- 6 years ago
- Views:
Transcription
1 Safety reporting requirements in the post marketing phase Pharmacovigilance Specialty Committee SQA Conference March 2017 Washington
2 DISCLAIMER These materials have been prepared solely for educational purposes and does not reflect the views of the author (s) employers. 2
3 Agenda Setting the stage Overview EU/Japan/USA Regulatory Requirements/Authorities PV Quality Management Systems (QMS) Audit/Self Inspection Qualified Person for Pharmacovigilance (QPPV) Unique requirements EU/Japan/USA Expedited Reporting Requirements EU/Japan/USA Aggregate Reporting Requirements EU/Japan/USA Additional Post Marketing Requirements Risk Management Post Marketing Studies
4 Setting the stage Pharmacovigilance has differing levels of importance in different parts of the world Most countries understand the concept of monitoring drug safety even though their legislation may not be mature (134 countries are part of the WHO Pharmacovigilance programme) The three most regulated markets with respect to pharmacovigilance are the EU, Japan and the USA The objectives of the requirements in these territories are similar in that they require licence holders to: Submit individual case reports Submit aggregate periodic reports Review safety data in order to manage risks
5 OVERVIEW EU/JAPAN/USA REGULATORY REQUIREMENTS/AUTHORITIES
6
7 Overview Regulations EU/Japan/USA Regulatory environment is the most complex Regs are less detailed than EU/Japan. Traditionally main concern has been on AE reporting so that FDA can perform signal detection (aggregate review of safety data), however it is shifting to also include quality systems (to ensure sponsors have appropriate processes to support safety activities The principles of the pharmacovigilance legislation and guidance in Japan is similar to that in Europe but there are some differences in the detail. FDA EMA and local Pharmaceuticals and Medical Devices Agency (PMDA) Ministry of Health Labour and Welfare (MHLW)
8 EU PV Requirements Hierarchy Regulation 1235/2010 and Directive 2010/84/EU: high level requirements. Directives and Regulations are available on the EMA website Implementing Measures Regulation (IMR) (520/2012): detailed requirements for MAHs (not in the Regulation or Directive) in relation to PSMF, QMS, monitoring of data in Eudravigilance, transmission of ICSRs, RMPs, PSURs and post authorisation safety studies (PASS) The Good Vigilance Practices (GVPs) contain the fine details Current Modules and their status are available on the EMA website Regulation & Directive Implementing Regulation Good Vigilance Practices
9 GVP Modules Key for QA Quality Systems PSMF PV Inspections PV Audits Risk Management Systems Management and Reporting of ADRs PSURs PASS Signal Management Additional Monitoring Safety Communication Risk Minimisation Measures Public Participation in PV Continuous PV, ongoing benefit risk evaluation, regulatory action International co operation
10 PV Quality Management Systems (QMS) Audit/self inspection EU JAPAN USA Risk based audits: Strategic: (long term approach) endorsed by upper management; Tactical: audit programme Operational: audit planning Mandatory Self Inspection (e.g., safety department performing periodic reviews & inspections of their key activities)
11 PV Quality Management Systems (QMS) Training and Procedures EU JAPAN USA Initial and ongoing training is expected for all personnel involved in PV tasks and MAHs are expected to have processes in place to check that training is effective. Education/ training requirements for PV staff Critical processes (as identified in GVPs) should be documented in written procedures Records retention requirements for PV records. Requirements on how to collect, classify and review safety information
12 Qualified Person for Pharmacovigilance (QPPV) EU JAPAN USA A named (QPPV) who has oversight of all aspects of The PV system and takes Overall responsibility for That system. (EU resident, trained/experienced in PV, a physician or access to one). Single person responsible for pharmacovigilance: Safety Management Supervisor (SNS) The SNS must be independent of the sales and marketing departments so that decisions about the product are based purely on protecting patient safety. Similar to the QPPV requirements in the EU, the SNS must have relevant experience
13 Unique requirements EU Pharmacovigilance System Master File (PSMF) 2012: New and describes the PV system in place and is a living document Company PV system and processes Sources of data Key roles (QPPV) Metrics to assess PV system performance Description of QMS Audits/CAPAs, plus various appendices (licensing partners, EU authorized product listings, computerised systems, log book of changes) Must be maintained in a current manner typically updated quarterly unless requested by regulatory authority (company then has 7 days to product current version)
14 Japan Regulatory bodies The Ministry of Health Labour and Welfare (MHLW) are ultimately responsible for the approval of medicines in Japan although the PMDA may carry out the review work. The Pharmaceuticals and Medical Devices Agency (PMDA) are responsible for implementing MHLW policy and day to day PV activities.
15 USA FDA FDA s requirements for postmarketing safety reporting for human drugs and biological products under 21 CFR , , , , and Section 760 of the Food Drug and Cosmetic Act (FDCA).
16 EU/JAPAN/USA EXPEDITED REPORTING REQUIREMENTS
17 Overview expedited reporting of Individual Case Safety Reports (ICSRs) Spontaneous source (days) Region/ Country Serious valid ICSRs (Domestic/ Foreign) calendar days Serious unexpecte dadr (Domestic/ Foreign) Death/oth er serious Serious expecte dadr (Domest ic ) Death/ other serious Serious & unexpected drug experiences (Domestic/ Foreign) NS valid ICSRs Domestic NS unexpected ADRs/infectio n reports Foreign NS Infection reports (Unexpect ed /expected Comment EU 15 (initial & follow up) 90 Japan /30 Aggregate/15 15/15 USA 15 (after initial receipt) Serious and unexpected drug experiences should be investigated and follow up reported in 15 calendar days.
18 EU/JAPAN/USA AGGREGATE REPORTING REQUIREMENTS
19 Aggregate reporting requirements EU JAPAN USA PSURs/PBRERs (Periodic Safety Update Reports / Periodic Benefit Risk Evaluation reports): evaluation riskbenefit balance of a medicinal product for submission by MAHs at defined time points during the post authorisation phase legislation: greater focus on benefit risk evaluation Data: AEs, where product is authorised, signals, labelling Periodic Safety Reports (PSR) Similar to PBRERs in the EU and produced after a product launch (domestic & foreign data). PBERS attached to PSR or data incorporated into PSR. NDA Annual Reports: Annual CMC, labelling, status updates of post marketing commitments or other postmarketing studies performed by, or on behalf of, the applicant Periodic reporting (PADER Periodic Adverse Drug Experience Report): 3 monthly for 3 yrs/then annually : Adverse drug experiences not previously expedited (e.g., serious expected AEs and non serious AEs), labeling changes, studies initiated With approved waiver from NDA requirements may submit PSUR in lieu (with line listings)
20 EU/JAPAN/USA ADDITIONAL POST MARKETING REQUIREMENTS
21 Additional Post Marketing Requirements: Risk Management EU USA JAPAN Risk Management Plan (RMP) All new product licences to have RMP to describe risks identified in relation to the product, measures implemented to manage risks and effectiveness of the measures RMPs do not all contain risk minimisation measures beyond conducting routine pharmacovigilance. Examples risk minimisation measures: Targeted Follow up questionnaires which need to be sent when a specific event occurs in association with a specific product Distribution of educational materials to HCP Specific training to be given to company staff (most commonly training for sales representatives) Post authorisation safety studies (PASS) by a specific deadline Risk Evaluation & Mitigation Strategies (REMS) Required when product label is not sufficient to manage the risks associated with the product e.g. products that are teratogenic if used by pregnant woman (Isotretinoin), products with a high abuse/misuse potential etc HCPs follow specific safety procedures prior to prescribing and dispensing the product e.g., lab/pregnancy monitoring, restricted distribution etc. MAH may need to prepare communication plans to inform HCPs of risks
22 Additional Post Marketing Requirements: Post Marketing Studies EU JAPAN USA Post Authorisation Safety Studies (PASS) any study relating to an authorised medicinal product conducted with the aim of identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicinal product, or of measuring the effectiveness of risk management measures. Early Post Marketing Phase Vigilance (EPPV) Post marketing surveillance studies after product launch at medical institutions who are visited by Medical Reps at the required frequency and EPPV Report is prepared and submitted at the end of EPPV period. Post marketing surveillance (PMS) For a period of time after product launch. Japanese Regulatory Agencies are likely to receive more safety data on the product vs spontaneous reporting Post Marketing Commitment (PMC) / Post Marketing Requirement (PMR) FDA can mandate additional studies to be conducted to further investigate safety profile (conditional approval)
23
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia
EudraVigilance Vet. and Pharmacovigilance of vet. Medicinal products in Serbia Presented by: Vladimir Raketić, DVM, spec; Audit /QM group Ministry of Agriculture, Forestry and Water Managment, Veterinary
More informationPSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector
PSMF in Practice Your Questions Answered! GPvP Symposium, 14 March 2014 Jonathan Rowell, Senior GPvP Inspector Content Answer industry questions related to the PSMF MHRA inspector s preparation: How we
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 3 19 June 2012 EMA/119871/2012 4 5 Guideline on good pharmacovigilance practices (GVP) Module III Pharmacovigilance inspections Draft finalised by the Agency in collaboration with Member States and
More informationPharmacovigilance - Regulatory perspective -
Pharmacovigilance - Regulatory perspective - Junko Sato Director for Risk Management, Office of Safety Pharmaceuticals and Medical Devices Agency (PMDA) Agenda Concept of Phamacovigilance Current Regulation
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816573/2011 Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file Draft finalised by the Agency in collaboration with Member States and submitted
More informationInterdependencies of Pharmacovigilance and Regulatory Affairs
Lorenz userbridge 2013 Budapest, September 17th Interdependencies of Pharmacovigilance and Regulatory Affairs Dr. rer. nat. Markus Dehnhardt Deputy QPPV Biologist Toxicologist Medical advisor Agenda 1.
More informationPharmacovigilance Legislation: The Impact of What Is Happening in Europe
Miranda Z. Dollen, BSc (Hons) 1 Abstract Pharmaceutical companies, regulatory agencies, and contract service organizations are managing substantial and ongoing changes to pharmacovigilance legislation
More informationMircea Ciuca, MD Global Head Medical & Clinical Drug Safety
Mircea Ciuca, MD Global Head Medical & Clinical Drug Safety Disclaimer The views and opinions expressed in this presentation are solely those of the presenter and do not necessarily reflect those of Vifor,
More informationPharmacovigilance and the Generic Industry
Pharmacovigilance and the Generic Industry Presented by Joan Janulis, RAC Vice President Lachman Consultant Services Inc. 2015 Lachman Consultant Services, Inc. All rights reserved. Legal Notice The information
More informationFourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation
Fourth Stakeholders forum on the implementation of the new Pharmacovigilance legislation Module II - Pharmacovigilance system master file Presented by: Joanna Harper Inspections, Enforcement & Standards
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationThe European Commission's Proposal to Re-design Existing European Drug Safety Rules. An Industry View on Practical Implications
The European Commission's Proposal to Re-design Existing European Drug Safety Rules An Industry View on Practical Implications Margaret Walters Merck, Sharp & Dohme Ltd. The Second International Pharmaceutical
More informationPharmacovigilance and the Generic Industry. Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi
and the Generic Industry Mark Vieder RPh MBA Director, Safety & Medical Writing Biorasi Disclaimer: This presentation has been prepared by Biorasi, LLC solely for the purpose of sharing information and
More informationEudraVigilance auditable requirement project
22 November 2017 EMA/835422/2016 Information Management Division EudraVigilance training plan (version 5) Project Maintenance Group 1 consultation 11 December 2015 Eudravigilance Expert Working Group consultation
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationSafety Measures in the new Pharmacovigilance System
Safety Measures in the new Pharmacovigilance System Dr. Harald Tietz Director Global Patient Safety & Regulatory Affairs, Germany Lilly Deutschland GmbH Documentation and reporting requirements: Centralisation
More informationNew EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change
New EudraVigilance functionalities and the 2010 pharmacovigilance legislation preparing for change Training Module PhV-M1 Overview of legal provisions that form the basis for the new EudraVigilance functionalities
More informationE2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES
E2B(R3): THE INSIDE SCOOP FOR PRODUCT SAFETY TEAMS IN LIFE SCIENCES PREPARING FOR E2B(R3) T he electronic transmission of adverse event information to stakeholders, using the International Conference on
More informationHOT TOPICS IN PV. Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva
HOT TOPICS IN PV International Society of Pharmacovigilance Establishing a good Pharmacovigilance system: Essential elements 2 January 2014 Petach Tikva Dr Irene FERMONT, MD, MSc, EUQPPV ISOP ISRAEL Coordinator
More informationExplanatory Note to GVP Module VII
31 October 2017 EMA/670256/2017 Human Medicines Evaluation Division Explanatory Note to GVP Module VII Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA), the procedure
More informationImportance of Pharmacovigilance for Pharmaceutical Industry
Importance of Pharmacovigilance for Pharmaceutical Industry JARIR AT THOBARI, MD, DPHARM, PHD FACULTY OF MEDICINE GADJAH MADA UNIVERSITY YOGYAKARTA, INDONESIA Role of Pharma Company Globally Investment
More informationE2B, Safety databases & Eudravigilance
E2B, Safety databases & Eudravigilance Delphine BERTRAM, PharmD Hospices Civils de Lyon France HOT TOPICS IN PV Hod Hasharon 7 May 2014 Dr Irene Fermont- ISOP ISRAEL Dganit Even Sapir -MSD Spontaneous
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/813938/2011 Rev 3* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 3) Date for coming into effect of first version 2 July 2012
More informationPharmacovigilance. Training session for patients and consumers involved in EMA activities, 25 November Presented by: Priya Bahri
Pharmacovigilance Training session for patients and consumers involved in EMA activities, 25 November 2014 Presented by: Priya Bahri An agency of the European Union 2 Pharmacovigilance - the science concerned
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/827661/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module IX Signal management (Rev 1) Date of coming into effect of first version 2 July 2012 Draft Revision 1* finalised
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/816292/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report Draft finalised by the Agency in collaboration with Member
More informationMedical Literature Monitoring
Medical Literature Monitoring 5 th Industry Platform on the implementation of EU pharmacovigilance legislation Presented by Tom Paternoster-Howe on 15 September 2015 EMA/Information Management/Data Standardisation
More informationWissenswertes aus dem Bereich PHV
Wissenswertes aus dem Bereich PHV Dr. Susanne Wolf Dept. Assessment Pharmacovigilance AGES-Gespräche Vienna, 15.09.2016 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH www.ages.at
More informationImplementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan
JCCT workshop on Q8/Q9/Q10 Beijing Implementation of 2005 Pharmaceutical Affairs Law and ICH Q8-Q10 in Japan Yukio HIYAMA Chief, 3 rd Section, Division of Drugs National Institute of Health Sciences, Ministry
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/827661/2011 (superseded version) Guideline on good pharmacovigilance practices (GVP) Module IX Signal management Draft finalised by the Agency in collaboration with Member States and submitted
More informationThe Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective
The Role of the Pharmacist in Pharmacovigilance A Regulatory Perspective Almath Spooner, Irish Medicines Board Pharmaceutical Society of Ireland National Pharmacy Summit, November 2008. Presentation Topics
More informationA practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance
FOR PHARMA & LIFE SCIENCES WHITE PAPER A practical guide to achieving and maintaining global oversight and ensuring end-to-end pharmacovigilance The increasing complexity of today s pharmaceutical industry
More informationQuestions And Answers To Support The
Questions And Answers To Support The Implementation Of The Pharmacovigilance Legislation - Update This Question and answers section gives advice on regulatory issues in on the interpretation and implementation
More informationPharmacovigilance: Information systems and services
Pharmacovigilance: Information systems and services Supporting business activities of the revised pharmacovigilance legislation through better information systems An agency of the European Union To deliver
More informationSaudi FDA Drug Approval Process. Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority
Saudi FDA Drug Approval Process Dr. Mohammed A. Alquwaizani Consultant- Chief of the scientific office Saudi Food and Drug Authority Objective Describe the drug regulation practice in Saudi Arabia and
More informationPharmacovigilance. An agency of the European Union
Pharmacovigilance An agency of the European Union Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related
More informationCOMPARISON OF PHARMACOVIGILANCE IN GERMANY AND JAPAN
COMPARISON OF PHARMACOVIGILANCE IN GERMANY AND JAPAN Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen
More informationDi Renzo Regulatory Affairs ROME - MILAN - LONDON
Di Renzo Regulatory Affairs ROME - MILAN - LONDON Di Renzo Regulatory Affairs In 1985, Di Renzo Regulatory Affairs began its regulatory consulting for medicines for human and veterinary use, food and dietary
More informationICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective
ISPE Japan Affiliate 2016 Annual Meeting, April 14-15, 2016, Tower hall Funabori, Tokyo, Japan ICH Q12 (Pharmaceutical Product Lifecycle Management): PMDA Perspective Yasuhiro Kishioka, Ph.D. Principal
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationPharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010
Pharmacovigilance Inspections Time to panic? Marie-Odile Hendrickx, DVM, MRCVS Pfizer Animal Health 13 December 2010 Content Legal basis What do agencies want? What happens Before During After How do you
More informationPMDA Perspectives Yoshihiro Matsuda, Ph.D.
PMDA Perspectives Yoshihiro Matsuda, Ph.D. Office of Standards and Guidelines Development Pharmaceuticals and Medical Devices Agency (PMDA) 1 Introduction of PMDA NAME: Pharmaceuticals and Medical Devices
More informationDRAFT Guidance Document for Industry - Preparation and Submission of Summary Reports for Marketed Health Products
DRAFT Preparation and Submission of Summary Reports for Marketed Health Products Annual Summary Reports and Issue-Related Summary Reports (effective date: Month dd, yyyy) Health Canada is the federal department
More informationSonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for Drug Evaluation and Research Food and Drug Administration
FDA Perspective on MedDRA Coding Quality in Post marketing Safety Reports European Informal MedDRA User Group Webinar Sonja Brajovic Medical Officer, Office of Surveillance and Epidemiology Center for
More informationReview of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance
Review of three years of Post Authorization Safety Studies (PASS) landscape under the 2010 European Pharmacovigilance Pierre Engel Priscilla Velentgas May 2016 Copyright 2016 Quintiles Your presenters
More informationMedical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS
Medical Device Regulatory Framework 9 SEPTEMBER 2015 FUNDISA CONFERENCE JANE ROGERS Key Topics Definitions Essential Principles Classification Conformity Assessment Framework License to Manufacture, Import,
More informationQ & A on PSUSA: Guidance document for assessors
31 October 2017 EMA/518909/2016 Human Medicines Evaluation Division Q & A on PSUSA: Guidance document for assessors Since the start of the Periodic Safety Update Report (PSUR) single assessment (PSUSA),
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationCMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES
CMD(h) GUIDANCE FOR MAHs ON THE PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN IN THE MUTUAL RECOGNITION & DECENTRALISED PROCEDURES 1. INTRODUCTION (BACKGROUND) November 2007 According to Article 8
More informationMonitoring safety of medicines for patients
Monitoring safety of medicines for patients Pharmacovigilance activities related to medicines for human use in the EU (COM(2016) 498) Health and Food Safety The information contained in this publication
More informationInformation on the Member States requirement for the nomination of a pharmacovigilane (PhV) contact person at national level
19 July 2017 EMA/INS/PhV/445316/2017 Committees and Inspections Information on the Member s requirement for the nomination of a pharmacovigilane (PhV) contact person at national level Based on Pharmacovigilance
More informationSystematic Risk Management: An Overview of ICH Q-9
Systematic Risk Management: An Overview of ICH Q-9 March 12, 2014 12014 ParagonRx International LLC Today s Session Systematic Risk Management: An Overview of ICH Q-9 Speakers: Jeff Fetterman, President,
More informationImplementing Benefit-Risk Management More Effectively
Implementing Benefit-Risk Management More Effectively Steve Mayall, Principal Consultant June 2017 Pope Woodhead & Associates Ltd. The Old Grammar School, 1 Ramsey Road, St. Ives, Cambridgeshire, PE27
More informationCHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS 2. PHARMACEUTICAL AND MEDICAL DEVICE ACT
CHAPTER 2 PHARMACEUTICAL LAWS AND REGULATIONS 1. PHARMACEUTICAL LAWS Pharmaceutical administration in Japan is based on various laws and regulations, consisting mainly of: (1) Pharmaceutical and Medical
More informationRegulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance
Regulatory Framework in Japan - Past and Future - Building a Regulatory Framework Essential Elements of Compliance / Surveillance Nobuo UEMURA Director Office of Medical Devices III Pharmaceuticals and
More informationReminder (VICH charter)
Dr. Marie Hendrickx Head of EU Pharmacovigilance Pfizer Animal Health IFAH Europe Representative VICH Electronic Standards Implementation Expert Working Group VICH Workshop Presentation of 2 Pharmacovigilance
More informationGuideline on the processing of renewals in the centralised procedure
22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation
More informationQ/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008
Q/A-LIST FOR THE SUBMISSION OF VARIATIONS ACCORDING TO COMMISSION REGULATION (EC) 1234/2008 1. General questions Doc. Ref: CMDh/132/2009/Rev.20 May 2013 Question 1.1 What is the definition of MAH? According
More informationPharmacovigilance- Content of the New EU Legislation and Challenges for BfArM
Pharmacovigilance- Content of the New EU Legislation and Challenges for BfArM 12 th DGRA Annual Congress June 15 to 16, Bonn U. Hagemann Bundesinstitut für Arzneimittel und Medizinprodukte BfArM Visit
More informationEMA pharmacovigilance system manual
13 October 2016 EMA/623550/2013 Inspections, Human Medicines Pharmacovigilance & Committees Division Version 1.2 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000
More informationEudraVigilance access policy for medicines for human use
23 August 2011 EMA/759287/2009 corr. Patient Health Protection Draft agreed by the EudraVigilance Expert Working Group December 2007 Consultation with the EudraVigilance Steering Committee February 2008
More informationUniversity joins Industry: Clinical Trials & Drug Safety. Aula Magna-Facultad de Farmacia 11 Marzo 2015
University joins Industry: Clinical Trials & Drug Safety Aula Magna-Facultad de Farmacia 11 Marzo 2015 Contents Background, key points and basic knowledge Department tasks and responsibilities Importance
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA
Post Marketing Safety Reporting (PMSR) Challenges and Successful Practices for Combination Products Objective Session Goals Summary of the final rule Interpretation for combination products approved as
More informationThe PRAC Roles and challenges Focus on RMPs and RMAs. Prof. Jean-Michel Dogné. Head of the Department of Pharmacy PRAC effective member
The PRAC Roles and challenges Focus on RMPs and RMAs Prof. Jean-Michel Dogné Head of the Department of Pharmacy PRAC effective member Rue de Bruxelles, 61 B-5000 Namur, Belgium Phone: 0032 (0)81 724289
More informationReport to the European Commission on Pharmacovigilance audits carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013
Report to the European Commission on Pharmacovigilance s carried out in the Bulgarian Drug Agency period of time from April 2011 to June 2013 1. INTRODUCTION This report provides an overview of the s conducted
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More informationContact Information: Rapture Biotech D-201, Sector - 10, Noida Uttar Pradesh. Phone , ,
Topics Covered: MODULE 1 Introduction To Pharmacovigilance Terminologies used in Pharmacovigilance ADRs Polypharmacy MODULE 2 Pharmacoepidemiology Iatrogenesis Prescription-event monitoring MODULE 3 SAE
More informationGuideline on good pharmacovigilance practices (GVP)
8 September 2014 EMA/873138/2011 Rev 1* (superseded version) Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products (Rev 1) Date
More informationGuideline on good pharmacovigilance practices (GVP)
9 October 2017 EMA/876333/2011 Rev 4* Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4) Date for coming into effect of first version 2 July 2012 Date for coming into effect
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationData Analytics Pharmacovigilance
Data Analytics in Pharmacovigilance - - Amit Srivastav Founder & Director, Infocorp Software Solution Executive Program in Business Analytics IIM Lucknow - 2014-1 How I Saved 7 Hours Per Day of a PV Org!
More informationProcedure management of variations
Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European
More informationSPECIAL EDITION. the backbone of clinical development
SPECIAL EDITION Medical writing the backbone of clinical development 2017 Medical Writing: The Backbone of Clinical Development Medical Writing for Submission to Asia-Pacific Regulatory Authorities The
More informationTopics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION
DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION Presentation to the FDA/Industry Conference sponsored by the School of Pharmacy at Temple University May 6, 2008 Topics Safety First initiative
More informationPost-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Post-marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER CSRC/DIA Think Tank June 3, 2016 Oanh Dang, PharmD, BCPS Division of Pharmacovigilance Safety Evaluator Office of Surveillance and
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationEudraVigilance NEU. Mag. pharm. Katharina Weber. BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz
EudraVigilance NEU Mag. pharm. Katharina Weber BASG/AGES Medizinmarktaufsicht Institut Überwachung - Abteilung Blut, Gewebe und Vigilanz AGENDA EudraVigilance neu Legal Requirements Process Change Management
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationINFORMATION ON JAPANESE REGULATORY AFFAIRS
2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationIndustry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions
Industry Perspective of US Combination Product Rule: Postmarket Safety Reporting Challenges and Proposed Solutions June 2017 By: Khaudeja Bano, Chair of the Combination Products Coalition (CPC) Postmarket
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationMedical Device Single Audit Program (MDSAP) Copyright 2014 BSI. All rights reserved.
Medical Device Single Audit Program (MDSAP) International Medical Device Regulatory Forum (IMDRF) IMDRF Management Committee (MC) regulators: Australia, Brazil, Canada, China, the European Union, Japan
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM January 2016 HPFBI CANADA (HEALTH CANADA) NNHPD NHPs Notice to Stakeholders Regarding Site Licensing Update Who s affected? Manufacturers, packagers, labellers, importers, and distributors
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationWork programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board
18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone
More informationRegulatory Overview Annex 11 and Part 11. Sion Wyn Conformity +[44] (0)
Regulatory Overview Annex 11 and Part 11 Sion Wyn Conformity +[44] (0) 1492 642622 sion.wyn@conform-it.com 1 Two Key Regulations Annex 11 21 CFR Part 11 Apply to the regulated company, but often have a
More informationGuide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationCobert's Manual of Drug Safety and Pharmacovigilance
JONES & BARTLETT G Cobert's Manual of Drug Safety and Pharmacovigilance Edition Barton Cobert, MD, FACP, FACG, BLCMD Associates Wcstfield. Jersey Introductions Contributors Noticc. xix. xxi 1 The Thcory
More informationClinical Trial Safety Reporting requirements
Clinical Trial Safety Reporting requirements SME info day 20 Mar 2017 Presented by Sophia Mylona Clinical & Non-clinical Compliance, European Medicines Agency An agency of the European Union Article Regulation
More information